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Background
Retroviral based biopharmaceuticals are used in numer-
ous therapeutic applications, from gene therapy to vacci-
nation [1-3]. Nonetheless, retroviruses are known to
incorporate proteins from the host cell which may
increase the vector immunotoxicity [4]. CD81, a mem-
brane protein belonging to the tetraspanin superfamily
has been recently identified as one of the host cell pro-
teins majorly incorporated into Moloney Murine Leuke-
mia Virus (MoMLV) derived vectors[5]. Therefore,
C D 8 1w a sc h o s e na sat a r g e tf o rs t u d y i n gt h ee f f e c t so f
host cell protein incorporation in the immunotoxic pro-
file of retroviral vectors (RV). A human cell line,
293rVLP, producing retrovirus like particles (rVLPs) was
used to prove the concept of customizing RV composi-
tion by manipulating cellular protein content, using the
CD81 tetraspanin as a case study. rVLPs will be used as
candidate vaccines for hepatitis C by displaying HCV-
E1/E2 proteins.
Materials and methods
Cell lines and culture media: 293rVLP is a HEK 293
(ATCC CRL-1573) based cell line established by stable
transfection of pCeB plasmid [6] driving MoMLV gag-
pol expression as described in [7]. 293T cells (ATCC
CRL-11268) were used for producing and titer shRNA
lentiviral vector stocks. All cells were maintained in Dul-
becco’s modified Eagle’s medium (DMEM) (Gibco) 10%
(v/v) Foetal Bovine Serum (FBS) (Gibco).
Plasmids and lentivirus production: Short hairpin (sh)
RNA lentiviral vectors based on pLKO.1-puro [8]
containing a puromycin resistance gene and targeting
five different sequences on the human CD81 mRNA or
a non-target (nt) shRNA vector were purchased from
Sigma Mission
® RNAi (Sigma). The lentiviral vector
stocks were produced by transient co-transfection of
293T cells with pSPAX2, pMD2G (Addgene) and the
respective pLKO.1-puro-shRNA.
Flow cytometry for CD81 detection: The presence of
CD81 on the cell membrane was detected by flow cyto-
metry using mouse monoclonal antibody against human
CD81 and an Alexa FluorR 488 dye conjugated second-
ary antibody (Invitrogen).
Oxidative stress induction and cell viability: The sus-
ceptibility to oxidative stress injury was assessed by ana-
lyzing tert-butyl hydroperoxide induced death. Cell
viability was quantified by the percentage of cells stain-
ing negative for PI (by flow cytometry).
RT activity: To determine MoMLV reverse transcrip-
tase (RT) activity the RetroSys C-Type RT activity kit
(Innovagen) was used.
Further details on Materials and Methods are in [9].
Results and discussion
293rVLP cells producing rVLPs were used to evaluate
the possibility of customizing vector composition by
manipulating host protein content. CD81 tetraspanin
w a sc h o s e nt ob ed o w n - r e g u l a t e db ys h R N A ,g i v e nt h a t
it is significantly incorporated into RV particles, confer-
ring them a strong immunogenic character in mice.
Each cell population, shCD81 8 to 12, as well as the
non-target control, were analyzed for the presence of
CD81 by flow cytometry (Table 1). CD81 down-regula-
tion efficiency varied considerably among the five
shRNA sequences, ranging from negligible in the case of
shCD81 11 to a very strong silencing effect in shCD81
10 cell population, with more than 90% of cells being
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totally positive (94%) for CD81. To increase CD81
down-regulation, the shCD81 10 cell population was
doubly infected with shCD81 9 and 12 (Table 1). Only
1.5% of the resulting cells were positive for CD81 which,
considering the background values for the ntshRNA
control (approx. 6%), suggested a totally CD81 silenced
population.
shCD81 9+10+12 cell population was cloned by limit-
ing dilution and 30 clones were isolated. Four of those,
#14, #19, #22 and #30 were chosen as representatives of
the highest CD81 silencing (≥85%) and #9 as a represen-
tative of intermediate CD81 silencing. The rVLP pro-
duction was analyzed by reverse transcriptase (RT)
quantification in the supernatant; the cellular response
to CD81 down-regulation and/or RNAi pathway activa-
tion was assessed by evaluating cell growth and cell
death susceptibility under oxidative stress conditions
(Table I). Cell population ntshRNA was used as negative
control to distinguish CD81 silencing from RNAi path-
way activation effects. The results were compared to the
parental cell line, 293rVLP. With the exception of clone
#14, all silenced clones presented lower cell growth.
This effect, seemed to be attributed to CD81 down-reg-
ulation, as it was not detected in the ntshRNA control.
Indeed, CD81 has been previously described to be impli-
cated in proliferation and cytostasis of various cell types,
including lymphocytes, fibroblasts, epithelial cells and
astrocytes [10-13]. Lower half maximal inhibitory con-
centration values (IC50) under oxidative stress were
observed for silenced cells, including the ntshRNA
population, suggesting that the activation of RNAi
pathway played a role in injury induced death suscept-
ibility. From a bioprocessing point of view, increased
susceptibility to stressful conditions, oxidative or other,
should be a drawback. However, RNAi is faster and sim-
pler than a knockout, and undeniably useful in prelimin-
ary stages. Additionally, for certain vital proteins, a total
knock-out may not be possible.
To assess rVLP productivity in shCD81 clones the RT
in the viral supernatant was quantified. Three of the five
clones presented lower RT productivities, whereas
clones #14 and #22 showed identical values to the non-
target silenced control or the parental cell line. This
suggested that CD81 down-regulation does not affect
viral particles production. Finally, rVLP shCD81 #14,
was used to produce rVLPs, which were concentrated,
purified and analyzed for the presence of CD81 by Wes-
tern blotting. The rVLPs were shown to be absent of
CD81 demonstrating that it could be eliminated. These
results suggest that, although naturally incorporated on
RV, CD81 is not essential for the assembly or secretion
of fully functional particles. Hepatitis C envelope pro-
teins E1/E2 were successfully expressed in CD81
silenced cells and incorporated in rVLPs.
Conclusions
In this work it was demonstrated that is possible to
manipulate the composition of the host cell proteins
incorporated into rVLPs. rVLps can be used as a epitope
display platform and used in vaccine development there-
fore, CD81 was chosen since it is strongly immunogenic
in mice. The results herein presented support that is
possible to manipulate cellular protein expression, CD81
Table 1 CD81 down-regulation in 293rVLP cells
CD81
- cells
(%)
sh populations ntshRNA 5.8
shCD81 8 20.4
shCD81 9 88.4
shCD81 10 92.8
shCD81 11 10.0
shCD81 12 31.0
shCD81 9+10
+12
98.5
CD81
- cells
(%)
Specific cell growth
(h
-1)
IC50 (µM tert-butyl
hydroperoxide)
Specific RT productivity (10
-6 ng/
cell.h)
293 rVLP 2.1 0.0201 ± 0.0002 3.3 ± 1.1 1.7 ± 0.3
ntshRNA 0.8 0.020 ± 0.002 9.2 ± 1.4 2.3 ± 0.4
shCD81 9+10+12
clones
shCD81 #9 86.4 0.0124 ± 0.0004 15.4 ± 1.0 0.9 ± 0.2
shCD81 #14 97.1 0.021 ± 0.002 4.5 ± 1.1 2.0 ± 0.4
shCD81 #19 92.9 0.015 ± 0.001 6.5 ± 1.1 1.2 ± 0.2
shCD81 #22 88.9 0.018 ± 0.001 6.0 ± 1.1 1.8 ± 0.4
shCD81 #30 82.3 0.017 ± 0.001 5.6 ±1.0 1.4 ± 0.2
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immunogenic profile. Additionally, for gene therapy pur-
poses, the removal immunotoxic proteins in the produ-
cer cell may improve the in vivo efficacy of retrovirus,
lentivirus or other enveloped virus.
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